Stock Analysis on Net
Stock Analysis on Net

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

Common-Size Income Statement
Quarterly Data

Vertex Pharmaceuticals Inc., common-size consolidated income statement (quarterly data)

Microsoft Excel
3 months ended: Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Product revenues, net 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 99.94 99.94 99.87 100.00 100.00
Other revenues 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.06 0.06 0.13 0.00 0.00
Revenues 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Cost of sales -14.54 -14.16 -14.06 -12.73 -14.62 -12.83 -12.38 -11.24 -12.30 -12.40 -11.92 -11.72 -11.94 -11.92 -12.71 -11.15 -12.48 -12.10 -12.10 -10.73
Gross profit 85.46% 85.84% 85.94% 87.27% 85.38% 87.17% 87.62% 88.76% 87.70% 87.60% 88.08% 88.28% 88.06% 88.08% 87.29% 88.85% 87.52% 87.90% 87.90% 89.27%
Research and development expenses -34.30 -31.60 -36.54 -29.33 -32.75 -32.62 -31.51 -31.27 -30.14 -27.63 -27.32 -28.66 -27.40 -23.54 -25.02 -26.35 -28.66 -32.08 -27.61 -29.60
Acquired in-process research and development expenses -3.00 -0.54 -168.17 -2.85 -0.71 -2.08 -4.43 -14.62 -0.98 -1.24 -2.82 -0.10 -6.10 -1.35 -53.44 -0.10 0.00 0.00 0.00 0.00
Sales, general and administrative expenses -12.97 -13.41 -14.07 -12.74 -14.66 -10.62 -10.53 -10.15 -11.61 -10.57 -9.80 -10.26 -12.31 -9.99 -10.85 -11.14 -13.01 -12.00 -12.58 -12.03
Change in fair value of contingent consideration 0.04 -0.01 -0.02 0.00 2.00 -0.05 0.02 0.08 -0.08 0.11 2.24 0.36 0.10 -0.06 -0.09 0.23 -0.03 -0.12 -0.60 -0.11
Income (loss) from operations 35.23% 40.27% -132.85% 42.35% 39.26% 41.80% 41.17% 32.80% 44.88% 48.27% 50.37% 49.63% 42.35% 53.15% -2.12% 51.49% 45.82% 43.70% 47.10% 47.54%
Interest income 4.40 4.77 5.92 6.73 7.13 6.76 5.80 5.16 3.73 1.98 0.49 0.08 0.06 0.06 0.06 0.08 0.14 0.20 0.28 0.83
Interest expense -0.10 -0.27 -0.37 -0.39 -0.42 -0.44 -0.45 -0.48 -0.50 -0.59 -0.66 -0.71 -0.73 -0.77 -0.86 -0.91 -1.00 -0.90 -0.91 -0.93
Other income (expense), net -0.51 -0.61 -0.87 -1.16 -0.39 -0.64 0.06 0.05 -1.35 0.74 -3.56 -3.47 0.34 2.14 0.45 -3.05 9.63 5.49 7.63 -4.03
Income (loss) before (provision for) benefit from income taxes 39.03% 44.16% -128.18% 47.54% 45.58% 47.48% 46.59% 37.54% 46.76% 50.40% 46.64% 45.52% 42.02% 54.57% -2.47% 47.61% 54.59% 48.49% 54.10% 43.40%
(Provision for) benefit from income taxes -7.68 -6.45 -7.65 -6.67 -7.10 -5.79 -9.86 -8.07 -11.20 -10.53 -9.74 -9.19 -4.87 -11.63 6.20 -9.73 -17.47 -5.10 0.82 -3.62
Net income (loss) 31.35% 37.71% -135.83% 40.87% 38.48% 41.69% 36.73% 29.47% 35.56% 39.86% 36.90% 36.33% 37.16% 42.94% 3.73% 37.88% 37.12% 43.39% 54.92% 39.78%

Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

Income statement item Description The company
Income (loss) from operations The net result for the period of deducting operating expenses from operating revenues. Vertex Pharmaceuticals Inc. income (loss) from operations as a percentage of revenues increased from Q2 2024 to Q3 2024 but then slightly decreased from Q3 2024 to Q4 2024.
Income (loss) before (provision for) benefit from income taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Vertex Pharmaceuticals Inc. income (loss) before (provision for) benefit from income taxes as a percentage of revenues increased from Q2 2024 to Q3 2024 but then slightly decreased from Q3 2024 to Q4 2024.
Net income (loss) The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Vertex Pharmaceuticals Inc. net income (loss) as a percentage of revenues increased from Q2 2024 to Q3 2024 but then slightly decreased from Q3 2024 to Q4 2024.